Information  X 
Enter a valid email address

Accrol Group Hldgs (ACRL)

  Print      Mail a friend

Thursday 07 June, 2018

Accrol Group Hldgs

Result of Open Offer

RNS Number : 5709Q
Accrol Group Holdings PLC
07 June 2018
 

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.  Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

7 June 2018

 

ACCROL GROUP HOLDINGS PLC
(AIM: ACRL)

 

Open Offer Closed, Admission of Open Offer Shares and Total Voting Rights

 

Accrol Group Holdings plc (the "Company" or "Accrol"), the AIM-listed leading independent tissue converter, notes that the open offer to raise up to £1.935 million described in the announcement dated 22 May 2018 titled "Open Offer" (the "Open Offer") closed for acceptances at 11.00 a.m. on 6 June 2018 in accordance with its terms. The Company reports that it has received valid applications in respect of a total of 37,108,972 new ordinary shares of £0.001 in the Company ("New Ordinary Shares"), representing a percentage take up of 287.64 per cent. of the New Ordinary Shares available under the Open Offer.

 

12,901,200 New Ordinary Shares are available under the Open Offer. All qualifying shareholders who applied for some or all of their basic entitlement to New Ordinary Shares under the Open Offer will have those applications satisfied in full. Qualifying shareholders who, in addition to applying in full for their basic entitlement to New Ordinary Shares under the Open Offer, applied for New Ordinary Shares under the excess application facility will have their applications under that facility satisfied on a basis that takes account of their respective holdings of shares in the Company as at 5.00 p.m. on 18 May 2018.

 

The aggregate amount raised pursuant to the Open Offer is approximately £1.935 million.

 

Application has been made for the 12,901,200 New Ordinary Shares to be issued pursuant to the Open Offer to be admitted to trading on AIM ("Admission"). It is expected that Admission and dealings in those shares will commence at 8.00 a.m. on 8 June 2018.

 

Immediately following Admission, there will be 195,246,536 ordinary shares of £0.001 in the capital of Accrol in issue, with one voting right each. The Company does not hold any shares in treasury. The number of ordinary shares with voting rights will therefore be 195,246,536. Accordingly, this number should be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

Enquiries:

 

Zeus Capital Limited (Nominated Adviser & Broker) 

Dan Bate / Andrew Jones                                                                                                     Tel: +44 (0) 161 831 1512

Dominic King / John Goold                                                                                                  Tel: +44 (0) 203 829 5000

 

Belvedere Communications Limited     

Cat Valentine ([email protected])                                                       Mob: +44 (0) 7715 769 078

 

 

Notes to Editors

 

Accrol Group Holdings plc, based in Lancashire, is a leading tissue converter and supplier of toilet rolls, kitchen rolls and facial tissues as well as other tissue products to major retailers throughout the UK. 

Accrol operates from three sites:

·      A manufacturing, storage and distribution facility in Blackburn;

·      A facial tissue plant, also in Blackburn; and

·      A manufacturing, storage and distribution facility in Leyland.

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCUGUUCQUPRGMQ

a d v e r t i s e m e n t